342 related articles for article (PubMed ID: 16192594)
1. Social support, psychological distress, and natural killer cell activity in ovarian cancer.
Lutgendorf SK; Sood AK; Anderson B; McGinn S; Maiseri H; Dao M; Sorosky JI; De Geest K; Ritchie J; Lubaroff DM
J Clin Oncol; 2005 Oct; 23(28):7105-13. PubMed ID: 16192594
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor concentration and social factors as predictors of natural killer cell activity in early-stage breast cancer patients. Confirmation of a model.
Levy SM; Herberman RB; Lee J; Whiteside T; Kirkwood J; McFeeley S
Nat Immun Cell Growth Regul; 1990; 9(5):313-24. PubMed ID: 2077396
[TBL] [Abstract][Full Text] [Related]
3. Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial.
Li Y; Yang GL; Yuan HY; Bai DJ; Wang K; Lin CR; Hu MB; Feng MH
Hepatogastroenterology; 2005; 52(62):504-8. PubMed ID: 15816467
[TBL] [Abstract][Full Text] [Related]
4. [The comparison of biological characteristics between tumor-infiltrating lymphocytes and tumor-associated lymphocytes in ascites of epithelial ovarian carcinoma].
Kang S; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 1998 Oct; 33(10):607-10. PubMed ID: 10806687
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cell activity depression in peripheral blood and ascites from gastric cancer patients with high TGF-beta 1 expression.
Yoon SJ; Heo DS; Kang SH; Lee KH; Kim WS; Kim GP; Lee JA; Lee KS; Bang YJ; Kim NK
Anticancer Res; 1998; 18(3A):1591-6. PubMed ID: 9673375
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
[TBL] [Abstract][Full Text] [Related]
7. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
[TBL] [Abstract][Full Text] [Related]
8. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer.
Costanzo ES; Lutgendorf SK; Sood AK; Anderson B; Sorosky J; Lubaroff DM
Cancer; 2005 Jul; 104(2):305-13. PubMed ID: 15954082
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of natural killer activity by tumor-associated lymphoid cells from ascites ovarian carcinomas.
Allavena P; Introna M; Mangioni C; Mantovani A
J Natl Cancer Inst; 1981 Aug; 67(2):319-25. PubMed ID: 6943371
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
Ikarashi H; Fujita K; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K
Cancer Res; 1994 Jan; 54(1):190-6. PubMed ID: 8261438
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma.
Schleypen JS; Baur N; Kammerer R; Nelson PJ; Rohrmann K; Gröne EF; Hohenfellner M; Haferkamp A; Pohla H; Schendel DJ; Falk CS; Noessner E
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):718-25. PubMed ID: 16467081
[TBL] [Abstract][Full Text] [Related]
12. [The effect of sera of breast cancer patients on NK cell activity].
Konjević G; Spuzić I
Srp Arh Celok Lek; 1995; 123(9-10):227-31. PubMed ID: 17974436
[TBL] [Abstract][Full Text] [Related]
13. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
14. Immunologic features of tumor-infiltrating lymphocytes and peripheral blood lymphocytes in ovarian cancer patients.
Schöndorf T; Engel H; Kurbacher CM; Brenne U; Kolhagen H; Göhring UJ; Scharl A; Mallmann P
J Soc Gynecol Investig; 1998; 5(2):102-7. PubMed ID: 9509389
[TBL] [Abstract][Full Text] [Related]
15. Immunological variations in women suffering from ovarian cancer. Influence of radical surgical treatment.
Rampone B; Rampone A; Tirabasso S; Panariello S; Rampone N
Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):116-9. PubMed ID: 11526704
[TBL] [Abstract][Full Text] [Related]
16. Human natural killer cells: a comprehensive review.
Sinkovics JG; Horvath JC
Int J Oncol; 2005 Jul; 27(1):5-47. PubMed ID: 15942642
[TBL] [Abstract][Full Text] [Related]
17. Defective natural killer activity within human ovarian tumors: low numbers of morphologically defined effectors present in situ.
Introna M; Allavena P; Biondi A; Colombo N; Villa A; Mantovani A
J Natl Cancer Inst; 1983 Jan; 70(1):21-6. PubMed ID: 6337291
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Tomsová M; Melichar B; Sedláková I; Steiner I
Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
[TBL] [Abstract][Full Text] [Related]
19. [Study on the TIL and NK of IL-2 injected via pelvic retroperitoneal space in gynecological cancer patient].
Chen J; Cao ZY; Zhang P; Peng ZL; Yang YL; Bi JH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):406-8. PubMed ID: 15181850
[TBL] [Abstract][Full Text] [Related]
20. Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer.
Lichtenstein AK; Berek J; Zighelboim J
J Natl Cancer Inst; 1985 Feb; 74(2):349-55. PubMed ID: 3856049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
